|Bid||106.70 x 800|
|Ask||106.85 x 900|
|Day's Range||106.54 - 107.43|
|52 Week Range||72.80 - 108.68|
|Beta (3Y Monthly)||0.24|
|PE Ratio (TTM)||25.38|
|Earnings Date||Jul 29, 2019 - Aug 2, 2019|
|Forward Dividend & Yield||2.98 (2.80%)|
|1y Target Est||106.19|
Something really interesting has happened to Plug Power (NASDAQ:PLUG). And it's not just the fact that the PLUG stock price has doubled so far in 2019. More interestingly, investors actually seem to have started to trust Plug Power stock.After all, Plug Power's earnings earlier this month missed analysts' average estimates badly. And while the miss was driven in part by accounting vagaries, even aside from those, the quarter looked relatively weak. * 5 Safe Stocks to Buy This Summer After 20 years on the public markets, and a wealth of disappointment, one might think the PLUG stock price would plunge on that type of news. That's doubly true, given how important 2019 is to Plug Power stock. Plug Power's management has promised positive adjusted EBITDA this year, a long-awaited (emphasis on both "long" and "awaited") target for Plug Power. It hardly looked like Plug Power was off to a good start.InvestorPlace - Stock Market News, Stock Advice & Trading TipsPLUG stock price did drop briefly, but it rebounded quickly. In fact, it now trades where it did before the report. Investors are giving PLUG the benefit of the doubt, which history suggests is dangerous. Will this time finally be different? The Case Against Plug Power StockThe case against PLUG at the moment is reasonably simple: this is the ultimate "show-me" stock, and it hasn't shown enough. Its Q4 results were positive in one way, but incredible in another: as Bloomberg noted, the company generated positive adjusted EBITDA for the first time in 20 years.In, those two decades Plug Power stock has repeatedly disappointed investors. On a split-adjusted basis, the PLUG stock price touched $1,000 during the dot-com bubble. It hit just above $7 in 2011, and $6 in 2014. A major deal with Amazon.com (NASDAQ:AMZN) caused PLUG stock price to double in 2017, but the gains were gone within 18 months.Given PLUG's history, there seems at least a significant risk that the 100%+ rise in PLUG stock price this year is another head fake. The company is targeting positive adjusted EBITDA this year, but even its operating cash flow will likely come in negative. And while PLUG stock price might seem cheap at about $2.50, Plug Power stock isn't cheap. The stock trades at 2.5 times its billings guidance for this year and about two times analysts' consensus revenue estimates for next year.It is, as I wrote even when I recommended PLUG stock, the ultimate "this time is different" story. Given that, as the old adage goes, those are the four most dangerous words in investing. investors should be cautious at the very least. The Case for PLUGBut maybe, just maybe, this time is different. Amazon isn't the only key customer: Walmart (NYSE:WMT) and Procter & Gamble (NYSE:PG) are on board as well. Plug Power CEO Andy Marsh has teased additional announcements this year, and backed his predictions by personally buying Plug Power stock.A pilot test with FedEx (NYSE:FDX) means Plug Power could expand beyond forklifts. Its debt has been refinanced, and Plug Power has roughly $100 million in cash on its balance sheet.Meanwhile, PLUG has started to deliver on its promises. Marsh predicted positive adjusted EBITDA for the second half of 2018, and Plug Power did reach that goal. Its 2019 guidance was well above expectations, helping to bring about the recent rally of Plug Power stock.And PLUG's underlying business model has some value. There's a reason investors have been upbeat about its outlook, in various forms, for twenty years. Hydrogen fuel cells offer real promise , and the backing from Amazon and Walmart (both of whom own warrants on Plug Power stock) doesn't hurt as well.History might not be favorable for Plug Power stock, but at this point it's just that: history. A stock is based on the net present value of its future cash flow. Plug's future looks much brighter than it has in quite a while. Be Careful Out ThereGoing forward, the run of PLUG looks like it may have gone too far, too fast. There is a lot riding on its Q2 results; investors are not going to tolerate another miss. And as seen in December, Plug Power stock can fall quickly if macro worries arise.Still, PLUG has an intriguing story, and if Plug Power can deliver, PLUG stock price can rise by a large amount. Investors are starting to believe this time is different; if they're right, the rally will continue.As of this writing, Vince Martin has no positions in any securities. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 5 Safe Stocks to Buy This Summer * The 5 Best Telecom Stocks to Buy Now * 6 Innovative Stocks With Big Long-Term Growth Potential Compare Brokers The post This Time Might Actually Be Different for Plug Power Stock appeared first on InvestorPlace.
A former Procter & Gamble executive has been hired as CEO of a research and development firm focused on marijuana and hemp products related to health and wellness.
Activist investor Nelson Peltz is well known for taking stakes in companies and pushing executives to make changes to increase the value of shares.
SINGAPORE, May 24, 2019 /PRNewswire/ -- Procter & Gamble (PG) today hosted the second annual Asia Pacific #WeSeeEqual Summit, bringing together eminent figures from private and public sectors to share their point of view on the underrepresentation of women in leadership roles, and call out on the need as leaders to impact change and accelerate progress for gender equality. This year, the focus of the #WeSeeEqual discussion centered on leaders' key role in changing the narrative about women by challenging the assumptions that still exist -- "myths" around women's leadership skills, their representation in science, technology, engineering and mathematics (STEM), or their ambitions -- and creating a new playbook that goes beyond re-writing talent systems, driving equality-based policies and practices, to broadening the current definition of leadership through the attention and action of both women and men alike.
Procter & Gamble has introduced reusable packaging that includes metal or glass bottles, which will be picked up from the homes of consumers who order brands via a new e-commerce site.
[Editor's note: This story was previously published in March 2019. It has since been updated and republished.]Cannabidiol (CBD) is emerging as a red-hot category of the marijuana industry. CBD consists of compounds in the cannabis sativa plant that do not produce a high. In fact, over the years, CBDs have been shown to have powerful therapeutic effects.Now it looks like the U.S. market could open up in a big way for this type of cannabis and several CBD stocks are gaining traction. The reason: In December, Congress passed the 2018 Farm Bill, which declared that CBD would no longer be treated as an illegal substance.InvestorPlace - Stock Market News, Stock Advice & Trading TipsSo how big could this opportunity be? Well, according to research from the Brightfield Group, the market in the U.S. could hit $22 billion by 2022. * 6 Stocks to Buy for This Decade's Massive Megatrend No doubt, this could move the needle for marijuana stocks -- and here's a look at seven that stand out: Marijuana Stocks Poised to Benefit From CBD Legalization: Cronos Group (CRON)Cronos Group (NYSE:CRON) operates a vertically integrated cannabis platform, with a presence across five continents. In terms of the CBD opportunity, the company recently struck a strategic partnership with Gingko Bioworks, which has raised $430 million. The company's founder, Tom Knight, is known as the "father of synthetic biology" and his innovations -- such as with software to print DNA -- should allow for the creation of cannabinoids at a massive scale. This is critical because it can be difficult to produce pure forms that are cost-effective and precise.CRON also has the advantage of substantial financial resources to commercialize its cannabinoids. Last December, Altria (NYSE:MO) invested $1.8 billion into the company for a 45% stake. The deal is certainly a validation of CRON but it will also allow for much broader distribution and improved product development.Of course, a company like MO does engage in substantial due diligence before making an investment. In the company's Q4 earnings call, CEO Howard Willard said: "We believe the growth opportunities are significant and will extend across the globe as cannabis markets open. Selecting the right partner in this category was critical and we've done just that. Cronos strong management team has built unique capabilities to compete globally across the medicinal, recreational and nutraceutical categories." Marijuana Stocks Poised to Benefit From CBD Legalization: Aurora Cannabis (ACB)Aurora Cannabis (NYSE:ACB), a Canadian based cannabis producer, has been building up its CBD business. Part of this has been with its investments in industrial hemp production, such as with the Radient facility in Edmonton. It is expected to get as much as 10,000 kilos per day.Next, ACB has been focused on revving up its product offerings. On its Q2 earnings call, Chief Corporate Officer Cam Battley said the company is poised "to launch a broad line of CBD based wellness product in the near future."What's more, ACB has been aggressive with its dealmaking. For example, it has increased its equity position in Hempco and purchased Agropro, which is Europe's largest hemp producer. * 6 Stocks to Buy for This Decade's Massive Megatrend Something else to keep in mind: Legendary billionaire investor Nelson Peltz has joined the company as an advisor. This is certainly a major vote of confidence. He not only has deep access to investment capital but a strong network of potential partners, especially in the consumer goods industry. Some of his investments include stakes in PepsiCo (NASDAQ:PEP), Procter & Gamble (NYSE:PG) and Mondelez (NASDAQ:MDLZ). Marijuana Stocks Poised to Benefit From CBD Legalization: Charlotte's Web (CWBHF)The inspiration for the founding of Charlotte's Web (OTCMKTS:CWBHF) was a CNN documentary -- in 2013 -- about Charlotte Figi, whose health was significantly improved because of a hemp extract.Fast forward to today: The company is the No. 1 brand for the hemp-derived CBD market in the U.S. It definitely helps that it has distribution across more than 3,000 retail locations.And yes, growth has been strong. In Q3, revenues jumped by 57% to $17.7 million and adjusted EBITDA came to $5.4 million, up 31%.To better capitalize on the CBD opportunity, CWBHF issued $71.5 million in stock. This will be for cultivation and production to meet surging demand. Here's what the company's CEO, Hess Moallem, had to say: "In general, broader consumer awareness of the benefits of cannabinoids, namely cannabidiol (CBD), and whole plant hemp extract is driving increased uptake in both our retail channels and within our e-commerce platform."In other words, it seems like a pretty good bet that the growth will continue for some time. Marijuana Stocks Poised to Benefit From CBD Legalization: Zynerba Pharmaceuticals (ZYNE)Zynerba Pharmaceuticals (NASDAQ:ZYNE) is a clinical-stage biotech company that develops cannabinoid therapies for a variety of rare diseases. They include: * Fragile X Syndrome (FXS): This is a developmental disability that has been known to cause autism spectrum disorder. FXS impacts 71,000 people in the U.S. and there are no drug indications for it. * Developmental and Epileptic Encephalopathies (DEE): This is an epilepsy syndrome that involves severe cognitive impairment. About 45,000 children and adolescents have this in the U.S. * Autism Spectrum Disorder (ASD): This includes autism and Asperger's syndrome. ASD affects less than 1 million pediatric and adolescent patients. * 6 Stocks to Buy for This Decade's Massive Megatrend ZYNE's main candidate is Zygel, which is a CBD formulation gel for transdermal delivery. As for the FXS treatment, there is expected to be a pivotal data release in the second half of this year. And if the trial is positive, then the company will file a New Drug Application (NDA) for Zygel in the first half of 2020. Marijuana Stocks Poised to Benefit From CBD Legalization: Canopy Growth (CGC)Since 2016, Canopy Growth (NYSE:CGC) has been building its CBD business, with a focus on consumer packaged goods. The company has since created a vertically integrated platform for that includes a set of technologies that have pending patents. What's more, the hemp division is expected to yield 7,000 kilos of hemp-derived CBD on an annual basis. Granted, this cannot be used in the U.S. market. Yet CGC is likely to be a solid partner. For example, the company struck a deal with Martha Stewart's Sequential Brands Group, so as to develop CBD remedies for pets.It helps that CGC has substantial resources, which came from a mega $4 billion investment from Constellation Brands (NYSE:STZ). STZ has a strong global footprint -- with operations in the U.S., Mexico, New Zealand, Italy and Canada -- as well as a set of well-known consumer brands, such as Corona Extra, Corona Light, Modelo Especial, Modelo Negra and Pacifico. All in all, there is quite a bit of synergy for CGC.In the meantime, the company is growing at a staggering pace. In Q3, its revenues soared by 282% to $83 million. Marijuana Stocks Poised to Benefit From CBD Legalization:GW Pharmaceuticals (GWPH)The origins of GW Pharmaceuticals (NASDAQ:GWPH) go back to 1998. It was then that Dr. Geoffrey Guy and Dr. Brian Whittle co-founded the company to focus on developing therapies using cannabinoid formulations to target areas like epilepsy, glioma and schizophrenia.As of today, the lead product is a liquid formulation of a CBD, called Epidiolex, which received FDA approval in 2018 (the expectation is that there will be an approval in Europe in the second quarter). The drug targets the rare conditions of Lennox-Gastaut syndrome (LGS) or Dravet syndrome, which are variations of epilepsy. Furthermore, there are other indications for Epidiolex, such as Tuberous Sclerosis Complex and Rett Syndrome. * 6 Stocks to Buy for This Decade's Massive Megatrend But of course, the company has other treatments. Note that GWPH is looking to get approval in the U.S. for Sativex, which is an oromucosal spray for multiple sclerosis. It is currently available in 25 countries. Marijuana Stocks Poised to Benefit From CBD Legalization: Horizons Marijuana Life Sciences ETF (HMLSF)If you do not want to buy individual CBD stocks, then you can consider an exchange-traded fund, such as the Horizons Marijuana Life Sciences ETF (OTCMKTS:HMLSF). With this, you'll get exposure to companies like Canopy Growth, Aurora, GW Pharamceuticals, HEXO and Tilray (NASDAQ:TLRY).In all, there are 59 stocks in the portfolio and the net assets are about $890 million (in Canadian currency).Tom Taulli is the author of High-Profit IPO Strategies, All About Commodities and All About Short Selling. Follow him on Twitter at @ttaulli. As of this writing, he did not hold a position in any of the aforementioned securities. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 6 Stocks to Buy for This Decade's Massive Megatrend * The 7 Best Stocks to Buy From the IPO ETF * 7 Athletic Apparel Stocks With Marathon Pace Compare Brokers The post 7 Marijuana Stocks to Play the CBD Trend appeared first on InvestorPlace.
Eight Cincinnati-based public companies are among the largest in the world, according to the 17th annual ranking by Forbes Media.
The Procter & Gamble Company (PG) today announced it is testing reusable packaging on some of its most popular products as part of LoopTM, a new effort that aims to change the world’s reliance on single use packaging and disposable waste. The circular e-commerce platform developed by international recycling leader TerraCycle will also “collect and recycle” some items like toothbrush heads and razor blades, creating circular solutions that help eliminate waste. Loop is a first of its kind global packaging and shopping circular solution which aims to improve environmental performance, as well as consumer convenience and affordability compared to current e-commerce solutions.
Procter & Gamble has expanded its offerings in the naturals category with the introduction of Tampax Pure organic tampons and Always Pure menstrual pads.
Tampax and Always, the leading period care brands from Procter & Gamble, introduce Tampax PURE, their new organic tampon option, and Always PURE pads – both free of dyes, fragrances, and chlorine bleaching that require no compromise on ingredients or protection. Tampax PURE tampons have a 100% organic cotton core and deliver the protection expected from Tampax every time. In speaking with thousands of tampon users in the last several years, it was clear that there was still a big unmet need in the natural menstrual category – an option that worked well,” said Amy Krajewski, Section Head Global Tampax Research & Development.
The well-known activist investor has reached a deal with Legg Mason Inc. that will net his fund three seats on the money manager's board of directors.
Procter & Gamble has completed the sale of 6.5 acres of its Gillette campus in South Boston, reportedly for $218 million.
PENJERLA/NEW DELHI, India (Reuters) - It was supposed to be Johnson & Johnson's biggest manufacturing plant in India. It was to eventually employ at least 1,500 people and help bring development to a rural area near Hyderabad in southern India. Two sources familiar with J&J's operations in India and one state government official told Reuters production at the plant, at Penjerla in Telangana, never began because of a slowing in the growth in demand for the products.
PENJERLA/NEW DELHI, India May 19 (Reuters) - It was supposed to be Johnson & Johnson's biggest manufacturing plant in India. It was to eventually employ at least 1,500 people and help bring development to a rural area near Hyderabad in southern India. Two sources familiar with J&J's operations in India and one state government official told Reuters production at the plant, at Penjerla in Telangana state, never began because of a slowing in the growth in demand for the products.
Retail sales, industrial production, and fixed asset investment all came in well short of estimates on a year-over-year basis. On Wednesday morning, the U.S. also reported some disappointing economic news. Retail sales, which were expected to rise 0.2% in the month of April, instead fell by 0.2%.
Nelson Peltz's firm, Trian Fund Management LP, is considering waging an activist fight to get Baltimore-based Legg Mason to improve its financial results, according to the Wall Street Journal.
The deal comes days after Boston-based General Electric Co. sold its headquarters campus for $252 million.
Thanks to another well-timed tweet by President Donald Trump, U.S. equities are bouncing back on Tuesday on fresh hope for a U.S.-China trade deal. Also helping was Trump's disputing of a New York Times report that the Pentagon is reviewing a military plan for Iran that involves sending 120,000 troops to the Middle East.This stands in stark contrast to the fears in play on Monday, with China vowing retaliatory measures including curtailing imports of Boeing (NYSE:BA) aircraft and the dumping of U.S. Treasury holdings. * 6 Trade War Stocks With a Lot of Risk The move was enough to push the Dow Jones Industrial Average back above its 200-day moving average and is focusing buyer attention on the handful of stocks that have largely ignored the month-long bout of volatility. Here are five worth a look:InvestorPlace - Stock Market News, Stock Advice & Trading Tips Consumer Stocks :Procter & Gamble (PG)Procter & Gamble (NYSE:PG) shares have shaken off the broad market pressure to keep marching higher, inching towards a new record high as it keeps riding support near its 50-day moving average. Shares were also barely affected by the volatility seen late last summer as well, continuing an uptrend that started in April 2018 that has seen shares gain more than 50%.The company is scheduled to next report results on July 30 before the bell. Analysts are looking for earnings of $1.05 per share on revenues of $16.9 billion. When the company last reported on April 23, earnings of $1.06 per share beat estimates by two cents on a 1.1% rise in revenues. Coca-Cola (KO)Shares of Coca-Cola (NYSE:KO) are rising up to challenge resistance from double-top highs near the $50-a-share threshold. Zooming out, the stock has been in a steady if somewhat choppy uptrend since the 2009 bear market low -- the very definition of what you would expect from a well-run consumer staples company. * 7 Dividend Stocks to Buy as the Trade War Reignites Results will next be reported on July 25 before the bell. Analysts are looking for earnings of 62 cents per share on revenues of $9.4 billion. When the company last reported on April 23, earnings of 48 cents per share beat estimates by two cents on a 5.2% rise in revenues. Colgate-Palmolive (CL)Shares of Colgate-Palmolive (NYSE:CL) are pushing higher to challenge highs the stock last set in early 2018. This continues a sideways channel that has been in place since the middle of 2016. Shares were recently upgraded to "buy" by analysts at Zacks, who are looking for a $80-a-share price target.The company will next report results on July 26 before the bell. Analysts are looking for earnings of 72 cents per share on revenues of $3.9 billion. When the company last reported on April 26, earnings of 67 cents per share beat estimates by a penny on a 2.9% drop in revenues. Management reaffirmed its relatively bright 2019 outlook as well. General Mills (GIS)General Mills (NYSE:GIS) shares are continuing to attempt a breakout up and over three-month resistance near the $52-a-share level, setting up a run at its early 2018 highs near the $57-a-share level. Such a move would be worth a gain of nearly 10% from here. Shares have been trading at a discount to the average consumer packaged goods stock this year, making its relative price stability even more valuable in these volatile times. * 7 Cloud Stocks to Buy on Overcast Days The company is scheduled to next report results on June 26 before the bell. Analysts are looking for earnings of 76 cents per share on revenues of $4.3 billion. When the company last reported on March 20, earnings of 83 cents per share beat estimates by 14 cents on an 8.1% rise in revenues. GoPro (GPRO)GoPro (NASDAQ:GPRO) is something of an unusual pick for this list, on account of its position as a turnaround consumer electronics name. Shares have cratered since reaching a high in late 2015, losing some 95% of their value into the low set in December. Since then, shares have been scrambling higher and are pushing up and over their April high today.The company will next report results on August 1 after the close. Analysts are looking for earnings of four cents per share on revenues of $301 million. When the company last reported on May 9, a loss of seven cents per share beat estimates by two cents on a 20.1% rise in revenues.As of this writing, William Roth did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 6 Trade War Stocks With a Lot of Risk * 7 Bond ETFs to Buy * 10 Stocks That Could Squeeze Short Sellers, Including CGC Compare Brokers The post 5 Consumer Stocks Ready to Push Higher appeared first on InvestorPlace.
French retailer Carrefour and U.S. waste recycling company TerraCycle launched on Tuesday the test for their 'Loop' initiative which they hope will tackle the problems of plastic waste threatening to destroy the environment. The 'Loop' online platform will allow shoppers in the Paris area to buy orange juice, powder detergent or shampoo in reusable containers that do not result in waste. Users put down a refundable deposit via the Loop website when ordering products, which are delivered in reusable glass and metal bottles, and shipped in a tote bag to shoppers' doors.
How quickly people think of recession and tariffs. Campbell's , Procter , Kimberly , Clorox get the money immediately. It's really insane of course because PG and KMB are so dependent upon China for growth but idiot money is at work and idiot money has a lot of money and ETFs to boot.
DEEP DIVE (This story has been updated with closing stock market prices.) Following a week of losses, investors were faced Monday with a heavy sell-off of U.S. stocks. Following President Trump’s decision to increase tariffs to 25% from 10% on $200 billion in annual imports from China, which went into effect Friday, China said it would set 25% tariffs on $60 billion in annual imports from the U.